No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 23 of the 40 quarters in the window, leaving 17 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 7.8x · 10Y median 11.6x · 27th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:24:12.396Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Verastem, Inc. (VSTM) stock was $7.75 as of Oct 6, 2026, 4:00 PM EDT, down 3.13% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -8.0% · 3-year avg -0.0%/yr · 5-year avg -25.2%/yr
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment.
Biotechnology · Needham, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.44
Revenue Est.
$29.32M
Last Quarter Results
EPS
$-0.31
vs Estimate
$-0.45
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1VSTM | $681.02M | $7.75 | -3.13% | -8.01% | -25.22% | -7.09% | N/A |
| 2SLDB | $681.27M | $6.92 | -1.98% | +19.56% | -27.50% | N/A | vs VSTM |
| 3AVR | $685.49M | $7.05 | -6.62% | +74.71% | N/A | N/A | vs VSTM |
| 4MDXG | $673.41M | $4.62 | +1.54% | -36.75% | -4.94% | -6.46% | vs VSTM |
| 5OLMA | $691.79M | $7.92 | -4.00% | -25.57% | -21.50% | N/A | vs VSTM |
| 6FTH | $693.19M | $26.89 | -0.77% | +182.36% | -31.75% | N/A | vs VSTM |
forward FY estimate
N/A
$40.08M
vs Estimate
$22.88M
Consensus Rating
Based on 9 analysts
Average Price Target
$14.67
+89.2% upside
Low
$11.00
Current
$7.75
High
$18.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.47 | $-0.46 | $-0.45 | 2 |
| Quarter ending Dec 2026 | $-0.40 | $-0.39 | $-0.37 | 2 |
| Quarter ending Mar 2027 | $-0.62 | $-0.58 | $-0.53 | 1 |
| Quarter ending Jun 2027 | $-0.65 | $-0.61 | $-0.55 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.66 | $-1.65 | $-1.63 | 5 |
| FY 2027 | $-1.77 | $-1.42 | $-1.06 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $28.96M | $29.32M | $29.68M | 5 |
| Quarter ending Dec 2026 | $34.40M | $34.56M | $34.71M | 5 |
| Quarter ending Mar 2027 | $36.06M | $38.76M | $40.73M | 4 |
| Quarter ending Jun 2027 | $38.82M | $41.73M | $43.85M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $117.02M | $117.93M | $119.36M | 7 |
| FY 2027 | $171.85M | $178.60M | $185.35M | 6 |
